Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97.2 mg Sacubitril / 102.8 mg Valsartan Bid in Patients With HFrEF
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Acronyms PARASAIL
- Sponsors Novartis
- 24 Jul 2017 Planned End Date changed from 30 Dec 2017 to 15 Nov 2017.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 14 May 2017.
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.